BriaCell Therapeutics Stock Forecast, Price & News

+0.02 (+0.62 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $3.26
50-Day Range
MA: $3.78
52-Week Range
Now: $3.26
Volume554,059 shs
Average Volume950,761 shs
Market Capitalization$2.52 million
P/E RatioN/A
Dividend YieldN/A
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:BCTX
Phone604 921 1810
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$2.52 million
Next Earnings Date7/5/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1867th out of 2,025 stocks

Biotechnology Industry

129th out of 148 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.02 (+0.62 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BriaCell Therapeutics (NASDAQ:BCTX) Frequently Asked Questions

What stocks does MarketBeat like better than BriaCell Therapeutics?

Wall Street analysts have given BriaCell Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BriaCell Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BriaCell Therapeutics' next earnings date?

BriaCell Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, July 5th 2021.
View our earnings forecast for BriaCell Therapeutics

Who are BriaCell Therapeutics' key executives?

BriaCell Therapeutics' management team includes the following people:
  • Dr. William V. Williams M.D., CEO, Pres & Director
  • Dr. Charles Louis Wiseman M.D., FACP, Founder & Director
  • Mr. Gadi Levin B.Com., C.A., M.B.A., CPA, MBA, CFO & Corp. Sec. (Age 48)
  • Ms. Farrah Dean, Mang. of Corp. Devel.

Who are some of BriaCell Therapeutics' key competitors?

When did BriaCell Therapeutics IPO?

(BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is BriaCell Therapeutics' stock symbol?

BriaCell Therapeutics trades on the NASDAQ under the ticker symbol "BCTX."

How do I buy shares of BriaCell Therapeutics?

Shares of BCTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BriaCell Therapeutics' stock price today?

One share of BCTX stock can currently be purchased for approximately $3.26.

How much money does BriaCell Therapeutics make?

BriaCell Therapeutics has a market capitalization of $2.52 million.

What is BriaCell Therapeutics' official website?

The official website for BriaCell Therapeutics is

How can I contact BriaCell Therapeutics?

The company can be reached via phone at 604 921 1810.

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.